Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
Recruiting · NCT06282796 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Echocardiography
What this trial is about
This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis.
Who can take part
Age range
18 Years to 80 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age ≥18 years
- Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy
- LVEF≥53% before chemotherapy
Exclusion criteria
- life expectancy ≤12 months
- Participating in other ongoing oncology clinical trials
- Prior treatment with anthracyclines or chest radiation therapy
- Pregnant or lactating women
- Ultrasound images of the heart are of very poor quality
Where it is running
5 locations listed.
- Fujian Cancer Hospital - Fuzhou, Fujian, China
- Dalian Friendship Hospital - Dalian, Liaoning, China
- Dalian Municipal Central Hospital - Dalian, Liaoning, China
- Liaoning Cancer Hospital & Institute - Shenyang, Liaoning, China
- The Third People's Hospital Of Chengdu - Chengdu, Sichuan, China